The use of BrainScope enables clinicians to determine if a brain bleed is likely, so they can decide if a patient needs to be expedited. It also provides an understanding of the potential presence of a functional injury so that appropriate post-concussion care is discussed before a patient is discharged. Due to its EEG capabilities, BrainScope is capable of detecting brain injuries that may not be visible on CT scans, opening up its potential use in cases that require MR exams.

“In BrainScope’s clinical FDA validation study, a negative predictive value of 98 percent was reported — meaning that if you were found to be BrainScope negative there was a very high likelihood that the patient did not have a brain injury visible on the CT scan,” said Singer. “Therefore, BrainScope One may be used in the future to help identify those patients who may need advanced neuroimaging (for example MR), who might be found to be CT-, but who have suffered a brain injury. This would help better, cost-effectively determine who needs imaging and what type of imaging, which could help ensure clinically appropriate scanning decisions.”


BrainScope is currently used in a range of healthcare settings, including urgent care and occupational health clinics, concussion clinics, hospital emergency rooms, the U.S. military, university sports and student health centers, professional sports, and pharmaceutical clinical trials.

New future clinical indications for the EEG-based platform are currently under consideration.

The findings were published in The American Journal of Emergency Medicine.

Back to HCB News

1

2(current)